Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02XXN
|
|||
| Former ID |
DNCL003802
|
|||
| Drug Name |
Evacetrapib
|
|||
| Synonyms |
LY2484595
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 3 | [1], [2] | |
| Company |
Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H36F6N6O2
|
|||
| Canonical SMILES |
CC1=CC(=C2C(=C1)C(CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C
|
|||
| InChI |
1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20?,22?,26-/m0/s1
|
|||
| InChIKey |
IHIUGIVXARLYHP-UXNJHFGPSA-N
|
|||
| CAS Number |
CAS 1186486-62-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
103911733, 135268436, 135626839, 137240261, 141386796, 141386797, 152258542, 160647376, 160699241, 160860498, 161005253, 162221695, 164194109, 170504191, 172096382, 198940733, 223390433, 223471431, 224462115, 225848218, 226482340, 226482535, 226508337, 244317218, 248331392, 249734743, 252155357, 252160892, 252166611, 252215734, 252471646, 252810963
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cholesteryl ester transfer protein (CETP) | Target Info | Inhibitor | [3] |
| Panther Pathway | CCKR signaling map ST | |||
| Reactome | LDL-mediated lipid transport | |||
| HDL-mediated lipid transport | ||||
| WikiPathways | Statin Pathway | |||
| Lipid digestion, mobilization, and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8401). | |||
| REF 2 | ClinicalTrials.gov (NCT02227784) A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol. U.S. National Institutes of Health. | |||
| REF 3 | The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.